Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined methostrexate and prednisone

G. Quintini*, V. Barbera, E. Ammatuna, V. Franco, A. M. Florena, G. Mariani

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

15 Citaten (Scopus)
7 Downloads (Pure)

Samenvatting

Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD)-type T-cell lymphoma has a very poor prognosis in most patients. Here we report a complete clinical response in a patient treated with low-dose oral methotrexate (10 mg/m2 weekly) in combination with prednisone (15 mg/day) in whom conventional chemotherapy was not effective. This regimen was not associated with major side effects. Our findings suggest that methotrexate may have beneficial effects in AILD-type T-cell lymphoma. Pilot clinical trials are needed to verify its efficacy in this setting.

Originele taal-2English
Pagina's (van-tot)880-881
Aantal pagina's2
TijdschriftHaematologica
Volume85
Nummer van het tijdschrift8
StatusPublished - 2000
Extern gepubliceerdJa

Citeer dit